Abstract:Abstract Blockade of programmed cell death protein 1 (PD-1) is approved for treatment of multiple human cancers and is the focus of multiple studies due to its key role in T cell function. However, only patients with ‘'hot'' tumors (i.e. those with increased numbers of tumor-infiltrating CD8+ T cells) respond well to the blockade. This suggests that new strategies to increase infiltration of CD8+ T cells into tumors will increase the number of tumor types and patients benefiting from anti-PD-1 therapy. CD5, a member of the scavenger receptor cysteine-rich (SRCR) superfamily, is expressed on T cells and a subset of B cells (B1a). It can attenuate TCR signaling and impair cytotoxic T lymphocyte (CTL) activation. CD5 knockout mice have increased anti-tumor immunity and reduced homograft tumor growth: reducing CD5 on CTLs may be therapeutically beneficial to enhance the anti-tumor response and increase tumor-infiltrating CD8+ T cells. We report that in vivo administration of anti-CD5 blocking MAb treatment increased primary T cell activation in response to 4T1 tumor cell homografts and ex vivo activation as measured by increased CD69, Fas, Fas ligand, IFNγ, PD-1, and apoptosis. Further, anti-CD5 treatment enhanced the capacity of primary T cells to kill 4T1 tumor cells ex vivo. Mice receiving anti-CD5 and anti-PD-1 in combination exhibited increased overall survival compared to mice treated with either agent alone. These data support the potential of blockade of CD5 function to enhance T cell-mediated anti-tumor immunity and PD-1 blockade treatment. Citation Format: Faizah Alotaibi, Mateusz Rytelewski, Rene Figueredo, Ronak Zareardalan1, Saman Maleki Vareki, Xiufen Zheng, Meng Zhang, Peter Ferguson, Mikal El-Hajjar, Yousef Najajreh, Wei-ping Min, James Koropatnick. Functional blocking of CD5 on T cells to enhance the efficacy of therapeutic PD-1 blockade in treatment of mouse 4T1 breast tumors [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 917.

Blocking C5aR Signaling Promotes the Anti-Tumor Efficacy of PD-1/PD-L1 Blockade

Blockade of C5a Receptor Unleashes Tumor-Associated Macrophage Antitumor Response and Enhances CXCL9-dependent CD8+ T Cell Activity

Targeting Depletion of Myeloid-Derived Suppressor Cells Potentiates PD-L1 Blockade Efficacy in Gastric and Colon Cancers.

Abstract 917: Functional Blocking of CD5 on T Cells to Enhance the Efficacy of Therapeutic PD-1 Blockade in Treatment of Mouse 4T1 Breast Tumors

Intracellular Activation of Complement C3 Leads to PD-L1 Antibody Treatment Resistance by Modulating Tumor-Associated Macrophages.

Complement receptor C5aR1 blockade reprograms tumor‐associated macrophages and synergizes with anti‐PD‐1 therapy in gastric cancer

PD-1 blocking strategy for enhancing the anti-tumor effect of CAR T cells targeted CD105

PD-1 signaling negatively regulates the common cytokine receptor γ chain via MARCH5-mediated ubiquitination and degradation to suppress anti-tumor immunity

Cancer‐associated Fibroblasts Promote PD‐L1 Expression in Mice Cancer Cells Via Secreting CXCL5

Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy

Non-canonical PD-1 signaling in cancer and its potential implications in clinic

C5aR1 is a Master Regulator in Colorectal Tumorigenesis Via Immune Modulation

Blockade of PD-1 Effectively Inhibits in Vivo Malignant Transformation of Oral Mucosa

Targeting Complement C5a to Improve Radiotherapy Sensitivity in Non-Small Cell Lung Cancer.

PD-1+ mast cell enhanced by PD-1 blocking therapy associated with resistance to immunotherapy

The C5a/C5aR1 axis promotes migration of tolerogenic dendritic cells to lymph nodes, impairing the anticancer immune response

TIGIT/CD155 blockade enhances anti-PD-L1 therapy in head and neck squamous cell carcinoma by targeting myeloid-derived suppressor cells

PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy

Blocking CX3CR1+ Tumor-associated Macrophages Enhances the Efficacy of Anti-PD-1 Therapy in Hepatocellular Carcinoma

Role of CXCR3 Signaling in Response to Anti-Pd-1 Therapy.

Blockade of PD-L1 Enhances Cancer Immunotherapy by Regulating Dendritic Cell Maturation and Macrophage Polarization